Add Yahoo as a preferred source to see more of our stories on Google. While influenza-like illness rates are stable and respiratory syncytial virus (RSV) cases are declining, whooping cough cases have ...

• RSV is the leading cause of infant hospitalization in the U.S. • Health officials urge vaccination for pregnant women, seniors, and people with medical risks. • Cases are climbing nationwide as flu ...

A study confirms the vaccine gives excellent protection for babies against life-threatening chest infections.

Coughing, sneezing and a runny nose: You might think it is yet another cold, but if your baby is under 2 years old, it could very well be respiratory syncytial virus (RSV). RSV is a virus infecting ...

The season of never-ending sneezing and stuffy noses is underway, sending Americans to pharmacy lines in hopes of keeping illness at bay with yearly shots. While flu and COVID-19 vaccines are an ...

Dallas County Health and Human Services’ virus surveillance dashboard shows at the end of March, 7.7% of RSV tests were positive, compared to under 4.5% last year. Texas is extending access to RSV ...

European Commission Approves Merck’s Enflonsia receives European approval for RSV lower respiratory tract disease in infants during their first RSV season: Rahway, New Jersey Mo ...

The CDC reports a highly mutated Cicada COVID variant BA 3.2 has been detected in at least 25 states including New Jersey in what could result in a summer surge of new COVID-19 cases, colliding with ...

We all know the risks of influenza and COVID for older people. But a third virus, RSV, can also land you in hospital. A free ...

Winter is a time for cosy weather, comforting meals, and family get-togethers, but it also increases the risk of viral infections. Lately, RSV has become a concern because of how it can affect ...

Respiratory season is underway and it’s important to review what vaccines and immunizations are recommended for our most vulnerable populations, which include people who are pregnant, and the babies ...

Enanta is in a strong position to dominate the largely untapped RSV therapeutics market with a Phase III trial on the horizon ...